Cosmo Technologies Ltd (sponsor), 2013-09: Phase 3 industry-sponsored registry record for oral methylene blue MMX tablets given before screening colonoscopy in 1249 participants, completed with results posted.
Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.
Cosmo Technologies Ltd (sponsor), 2013-09: Phase 3 industry-sponsored registry record for oral methylene blue MMX tablets given before screening colonoscopy in 1249 participants, completed with results posted. Record field quote (primary outcome description transcribed from the registry), hence MEDIUM. Sponsor: Cosmo Technologies Ltd (Italy). Phase 3. Status COMPLETED; enrollment 1249; start 2013-09; primary completion 2016-10; HAS RESULTS posted. Comparator: placebo tablets with split-dose bowel preparation. Companion publication is MTM-09 (Repici et al., Gastroenterology 2019). The maker of the product tested – Cosmo Technologies – is also the sponsor, which is a direct commercial interest in the result. Study type: regulatory record.
